Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Dell Seton Medical Center at The University of Texas — Austin, Texas
- University of Texas at Austin — Austin, Texas
- Saint Joseph Regional Cancer Center — Bryan, Texas
- MD Anderson in The Woodlands — Conroe, Texas
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - Gulf Coast — Beaumont, Texas
- Texas Oncology - Northeast Texas — Denison, Texas
- Texas Oncology - Northeast Texas — Denton, Texas
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Texas: - Texas Oncology - DFW — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- US Oncology Investigational Product Center (IPC) — Irving, Texas
- US Oncology Investigational Products Center (IPC) — Irving, Texas
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
- Scott and White Memorial Hospital — Temple, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Texas: - Texas Oncology West Texas — Abilene, Texas
- Parkland Health and Hospital System — Dallas, Texas
- Texas Oncology DFW — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Texas: - Clinical Study Site — Fort Worth, Texas
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Texas: - Texas Oncology - DFW ( Site 8002) — Dallas, Texas
- UT Southwestern Medical Center ( Site 0059) — Dallas, Texas
- Texas Oncology - Northeast Texas ( Site 8001) — Denison, Texas
- Texas Oncology - San Antonio ( Site 8004) — San Antonio, Texas
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2, Phase 3 Recruiting Academic/Other
A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy…
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
NCT ID: NCT03051464
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
- Oncology Consultants — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology Dallas — Irving, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- UTSW - Moody Outpatient Center - Parkland Health — Dallas, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Texas: - Investigative Site — Kingwood, Texas
- Investigative Site — Laredo, Texas
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Texas: - UT Health San Antonio MD Anderson Cancer Center — San Antonio, Texas
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Texas: - Texas Oncology - Central/South Texas /ID# 275154 — Austin, Texas
- The Center For Cancer And Blood Disorders /ID# 278512 — Fort Worth, Texas
- Texas Oncology-Grapevine /ID# 275155 — Grapevine, Texas
- The University of Texas MD Anderson Cancer Center /ID# 273539 — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, two-part trial in participants with FAP.
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT05552755
Sites in Texas: - Genetic Cancer Prevention Clinic - UT Southwestern — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Sponsor: AstraZeneca
NCT ID: NCT06792695
Sites in Texas: - Research Site — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas: - Houston Methodist Hospital — Houston, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT06948448
Sites in Texas: - Baylor Scott & White Medical Center — Temple, Texas
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Texas: - The University of Texas MD Anderson Cancer Center - Texas Medical Center — Houston, Texas